Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.7
3.0
Journals
JCM
Special Issues
New Clinical Advances in Psoriasis and Psoriatic Arthritis
share announcement

New Clinical Advances in Psoriasis and Psoriatic Arthritis

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Dermatology".

Deadline for manuscript submissions: 31 July 2025 | Viewed by 10729

Special Issue Editors

Dr. Diego Orsini

E-Mail Website
Guest Editor
Clinical Dermatology Unit, San Gallicano Dermatological Institute IRCCS, 00144 Rome, Italy
Interests: psoriasis; psoriatic arthritis; atopic dermatitis; eczema; pityriasis versicolor; venereology
Dr. Alessandra Narcisi

E-Mail Website
Guest Editor
1. Dermatology Unit, IRCCS Humanitas Research Hospital, 20089 Rozzano, MI, Italy
2. Department of Biomedical Sciences, Humanitas University, 20072 Pieve Emanuele, MI, Italy
Interests: psoriasis; biologics; atopic dermatitis; inflammatory skin diseases; translational research
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Psoriasis is a common, chronic, inflammatory, immune-mediated skin disease with a high prevalence worldwide. It is a chronic, relapsing–remitting, inflammatory autoimmune disease involving several factors. The complexity of psoriasis is also reflected in the comorbidities that accompany psoriasis, mainly affecting the skin and joints.

Recent therapeutic advances in psoriasis and psoriatic arthritis are compelling. We now have multiple options for treating the patient in front of us, but this also creates the dilemma of making the right treatment choice. This Special Issue aims to accumulate the latest reviews and original articles on psoriasis and psoriatic arthritis, with the aim of exploring the latest developments in all aspects of psoriasis and contributing to decision-making in our daily medical practice.

Dr. Diego Orsini
Dr. Alessandra Narcisi
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • psoriasis
  • psoriatic arthritis
  • inflammatory skin disease
  • inflammatory autoimmune disease
  • immunotherapy
  • autoimmunity
  • comorbidities
  • therapeutic
  • diagnosis
  • treatment
  • management
  • biologics

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (6 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review, Other

12 pages, 432 KiB  
Article
Effectiveness of Brodalumab for the Treatment of Moderate-to-Severe Psoriasis: A Retrospective, Real-World Multicenter Study with a Focus on Obese and Multi-Failure Patients—IL PSO (Italian Landscape Psoriasis)
by Diego Orsini, Dario Graceffa, Martina Burlando, Anna Campanati, Elena Campione, Claudio Guarneri, Alessandra Narcisi, Paolo Pella, Paolo Romita, Massimo Travaglini, Leonardo Zichichi, Luisa Maria Halina Arancio, Ginevra Baggini, Riccardo Balestri, Tommaso Bianchelli, Luca Bianchi, Alexandra Maria Giovanna Brunasso, Anna Elisabetta Cagni, Giacomo Caldarola, Gianluca Calianno, Anton Carpentieri, Martino Carriero, Andrea Carugno, Franco Cona, Antonio Costanzo, Emanuele Claudio Cozzani, Giacomo Dal Bello, Giovanni Carlo Lazzaro Danzuso, Annunziata Dattola, Marianna Donnarumma, Elena De Col, Maria Esposito, Carmen Silvia Fiorella, Marco Galluzzo, Francesca Graziola, Gaetano Licata, Matteo Licciardello, Agostina Legori, Piergiorgio Malagoli, Federica Mola, Gaia Moretta, Andrea Muracchioli, Attilia Musumeci, Maria Letizia Musumeci, Gianluca Pagnanelli, Vincenzo Panasiti, Lucia Peterle, Eugenio Provenzano, Marco Rubatto, Oriele Sarno, Davide Strippoli, Fabrizio Vaira and Maria Concetta Fargnoliadd Show full author list remove Hide full author list
J. Clin. Med. 2025, 14(4), 1087; https://doi.org/10.3390/jcm14041087 - 8 Feb 2025
Viewed by 933
Abstract
Background/Objectives: Brodalumab is a monoclonal antibody against the anti-IL-17 receptor A, approved for patients with moderate-to-severe psoriasis. This retrospective study investigated patients in clinical practice to assess the impact of body weight and previous treatments with biologics on the effectiveness of brodalumab. [...] Read more.
Background/Objectives: Brodalumab is a monoclonal antibody against the anti-IL-17 receptor A, approved for patients with moderate-to-severe psoriasis. This retrospective study investigated patients in clinical practice to assess the impact of body weight and previous treatments with biologics on the effectiveness of brodalumab. Methods: Patients were treated according to clinical practice, and assessed at baseline, 16, 36 and 52 weeks by means of the Psoriasis Area Severity Index (PASI) and DLQI score. Overall, 299 patients were included (147 naïve to biologics). Results: Mean PASI was significantly reduced compared with the baseline in the overall population by week 4 and continued to decrease at each study time point (15.9 ± 7.9 at baseline, 5.4 ± 5.3 at week 4, 1.9 ± 3.6 at week 6, 1.0 ± 2.1 at week 36, and 0.8 ± 2.1 at week 52; p < 0.001 at each control). PASI improved significantly both in bio-naïve and bio-experienced patients (p < 0.001). The proportions of patients achieving PASI 75, PASI 90, and PASI 100 were comparable between the bio-naïve and bio-experienced groups at all time points. The percentages of patients who achieved PASI 75 were similar in obese and non-obese subjects at all determinations except the visit performed after 36 weeks of treatment (94.3% non-obese vs. 83.1% obese, p = 0.005). PASI 90 was achieved more frequently among non-obese patients than obese patients after 36 weeks (80.7% vs. 64.4%, p = 0.008) and 52 weeks of treatment (84.1% vs. 71.7%, 0.027). The probability of achieving PASI 75 and PASI 100 was independent of nutritional status at any time during the study. Conclusions: In conclusion, our results confirm that brodalumab has both rapid and sustained effectiveness in patients with moderate-to-severe psoriasis; our results could be extended to patients with multiple risk factors impairing treatment response, such as multiple biological failure and obesity. Full article
(This article belongs to the Special Issue New Clinical Advances in Psoriasis and Psoriatic Arthritis)
►▼ Show Figures

Figure 1

13 pages, 1464 KiB  
Article
Psychological Aspects of Cutaneous Pain in Psoriasis
by Magdalena Kotewicz, Piotr K. Krajewski, Andrzej K. Jaworek and Jacek C. Szepietowski
J. Clin. Med. 2024, 13(16), 4890; https://doi.org/10.3390/jcm13164890 - 19 Aug 2024
Cited by 1 | Viewed by 1138
Abstract
Introduction: Psoriasis is a chronic inflammatory disease that negatively impacts patients’ quality of life (QoL) and mental health. Itch and pain are prevalent symptoms of psoriasis and contribute to the psychosocial burden of this disease. This study aimed to evaluate the impact of [...] Read more.
Introduction: Psoriasis is a chronic inflammatory disease that negatively impacts patients’ quality of life (QoL) and mental health. Itch and pain are prevalent symptoms of psoriasis and contribute to the psychosocial burden of this disease. This study aimed to evaluate the impact of skin pain on the prevalence and severity of symptoms of anxiety and depression and on the QoL in psoriasis patients. Methods: The studied population comprised 106 adults with psoriasis (34% female; mean age 42.1 ± 13.0 years). Disease severity was measured with the Psoriasis Area and Severity Index (PASI). The intensity of skin pain was assessed with the NRS and the Short Form McGill Pain Questionnaire (SF-MPQ). The Generalized Anxiety Disorder-7 (GAD-7) and Patient Health Questionnaire-9 (PHQ-9) questionnaires were used to estimate the severity of depression and anxiety, respectively, as was the Hospital Anxiety and Depression Scale (HADS). Quality of life (QoL) was studied using the Dermatology Life Quality Index (DLQI). Results: Regarding anxiety assessment, females reported significantly higher scores with the HADS-A (8.42 ± 4.85 points vs. 5.14 ± 3.9 points; p < 0.001) and the GAD-7 compared to men (7.50 ± 5.58 points vs. 5.24 ± 4.79 points; p = 0.036). Similarly, the severity of depression was significantly higher in women, as measured with the PHQ-9 (7.50 ± 5.58 points vs. 5.24 ± 4.79 points, p = 0.021). Psoriasis patients with skin pain scored significantly higher in HADS Total score (p = 0.043), HADS-A (p = 0.022), PHQ-9 (p = 0.035), and DLQI (p < 0.001) than the rest of the studied group. The intensity of skin pain measured with the SF-MPQ correlated significantly with HADS Total score (p = 0.021), HADS-A (p < 0.001), HADS-D (p = 0.038), and PHQ-9 (p < 0.001). Additionally, there was a significant correlation between the intensity of cutaneous pain assessed using the VAS and the PHQ-9 (p = 0.022). Conclusions: Skin pain significantly influences the well-being of patients with psoriasis as well as the symptoms of anxiety and depression. In particular, women with psoriasis are at increased risk of developing anxiety and depression. Our findings underline the necessity for a multidisciplinary approach to the management of this dermatosis. Full article
(This article belongs to the Special Issue New Clinical Advances in Psoriasis and Psoriatic Arthritis)
►▼ Show Figures

Figure 1

13 pages, 887 KiB  
Article
Platelet Reactivity in the Exacerbation of Psoriasis
by Piotr Adamski, Urszula Adamska, Katarzyna Buszko, Joanna Sikora and Rafał Czajkowski
J. Clin. Med. 2024, 13(4), 965; https://doi.org/10.3390/jcm13040965 - 8 Feb 2024
Viewed by 1524
Abstract
Background: Psoriasis is a chronic, inflammatory, immune-mediated disease with a specific cutaneous presentation. Increased platelet aggregation has been observed in patients with extensive psoriatic lesions. The aim of this study was to evaluate the clinical factors affecting platelet reactivity in patients with an [...] Read more.
Background: Psoriasis is a chronic, inflammatory, immune-mediated disease with a specific cutaneous presentation. Increased platelet aggregation has been observed in patients with extensive psoriatic lesions. The aim of this study was to evaluate the clinical factors affecting platelet reactivity in patients with an exacerbation of psoriasis. Methods: This was a prospective, single-center, observational study, enrolling patients hospitalized for an aggravation of psoriasis. Enrolled patients underwent single platelet function testing with light transmission aggregometry on the first morning of hospitalization. Results: 120 patients were enrolled in the study. Of the compared subgroups, women had higher maximal platelet aggregation (MPA) than men (77% vs. 72%; p = 0.03), and those with BMIs < 25 kg/m2 showed higher platelet reactivity compared to subjects with BMIs ≥ 25 kg/m2 (75% vs. 73%; p = 0.02). There was a positive correlation between MPA and platelet count (r = 0.27; p < 0.01), as well as C-reactive protein concentration (r = 0.20; p = 0.03), while a negative correlation was observed with total cholesterol (r = −0.24; p = 0.01) and triglycerides (r = −0.30; p < 0.01). A two-step analysis based on multidimensional models with random effects revealed that every increase in the platelet count by 103/μL led to an increase in MPA by 0.07% (R2 = 0.07; p < 0.01), and an increase in triglycerides’ concentration by 1 mg/dL was related to a reduction in MPA by 0.05% (R2 = 0.07; p < 0.01). Conclusions: The increased platelet reactivity observed in patients with psoriasis appears to be multifactorial and related to several clinical and laboratory features. Further research is warranted to put these findings into a clinical perspective. Full article
(This article belongs to the Special Issue New Clinical Advances in Psoriasis and Psoriatic Arthritis)
►▼ Show Figures

Graphical abstract

Review

Jump to: Research, Other

22 pages, 346 KiB  
Review
How Hormonal Balance Changes Lives in Women with Psoriasis
by Fortunato Cassalia, Anna Lunardon, Giovanni Frattin, Andrea Danese, Francesca Caroppo and Anna Belloni Fortina
J. Clin. Med. 2025, 14(2), 582; https://doi.org/10.3390/jcm14020582 - 17 Jan 2025
Cited by 2 | Viewed by 1720
Abstract
Psoriasis is a chronic, immune-mediated skin disease significantly impacting women, with disease severity often modulated by hormonal fluctuations. This review examines the influence of hormonal changes on the course of psoriasis in women, focusing on key life stages—including the menstrual cycle, pregnancy, postpartum, [...] Read more.
Psoriasis is a chronic, immune-mediated skin disease significantly impacting women, with disease severity often modulated by hormonal fluctuations. This review examines the influence of hormonal changes on the course of psoriasis in women, focusing on key life stages—including the menstrual cycle, pregnancy, postpartum, and menopause—and their impact on disease progression and symptomatology. Estrogen, the principal female sex hormone, plays a critical role in immune modulation. Variations in estrogen levels, which occur naturally throughout a woman’s life, are associated with fluctuations in psoriasis severity. Low estrogen levels, as seen during menstruation or menopause, are linked to symptom exacerbation, while elevated levels during pregnancy may reduce symptoms in some women. However, responses are variable, with others experiencing no change or worsening during pregnancy. Postpartum, the rapid decline in estrogen often triggers severe flare-ups, while menopause, marked by a sustained estrogen reduction, frequently correlates with increased disease severity and flare frequency. The review also addresses the profound impact of psoriasis on women’s quality of life, including physical discomfort, psychological distress, and social stigma. Additionally, fertility concerns are discussed, as severe psoriasis and associated treatments may increase the risk of adverse pregnancy outcomes. Consideration is given to hormonal therapies, lifestyle modifications, and their effects on psoriasis, underscoring the need for personalized treatment approaches that account for hormonal influences. Understanding these hormonal dynamics is essential for developing targeted, effective management strategies that enhance quality of life for women affected by psoriasis. Full article
(This article belongs to the Special Issue New Clinical Advances in Psoriasis and Psoriatic Arthritis)
21 pages, 3872 KiB  
Review
Updates on Psoriasis in Special Areas
by Alexandra-Irina Butacu, Cristian Toma, Iulia-Elena Negulet, Ionela Manole, Angela Nina Banica, Alexandra Plesea, Ioana Alexandra Badircea, Isabela Iancu and George-Sorin Tiplica
J. Clin. Med. 2024, 13(24), 7549; https://doi.org/10.3390/jcm13247549 - 11 Dec 2024
Cited by 2 | Viewed by 2009
Abstract
Special areas of involvement in psoriasis include the scalp region, the palms and soles, genital areas, as well as intertriginous sites. The involvement of these topographical regions is associated with important physical and emotional implications, resulting in reduced quality of life, social isolation, [...] Read more.
Special areas of involvement in psoriasis include the scalp region, the palms and soles, genital areas, as well as intertriginous sites. The involvement of these topographical regions is associated with important physical and emotional implications, resulting in reduced quality of life, social isolation, and work disability. Palms and soles can be affected as part of the generalized form of psoriasis or can be exclusively affected as palmo-plantar psoriasis. Nail involvement may be encountered in 10–55% of patients with psoriasis, while scalp involvement occurs in 45–56% of individuals with psoriasis. Genital involvement may be the only manifestation of cutaneous psoriasis in 2–5% of patients. Inverse or intertriginous psoriasis represents a special variant of psoriasis as it may mimic and be difficult to differentiate from other dermatological entities that involve the intertriginous skin, such as bacterial or fungal infections, eczema, or lichen planus. Treatment of psoriasis in special areas is challenging due to the facts that special areas are more resistant to standard therapies and are more sensitive to potent local treatments. Biological therapies, proven to be more efficient than standard therapies, are not widely available in the absence of extensive skin involvement. This manuscript aims to provide an up-to-date literature review on psoriasis in special areas, benefiting the everyday clinical practice of physicians in optimizing the evaluation and treatment of their patients. Full article
(This article belongs to the Special Issue New Clinical Advances in Psoriasis and Psoriatic Arthritis)
►▼ Show Figures

Figure 1

Other

Jump to: Research, Review

40 pages, 2040 KiB  
Systematic Review
An Overview of Growth Factors as the Potential Link between Psoriasis and Metabolic Syndrome
by Mateusz Matwiejuk, Hanna Myśliwiec, Adrian Chabowski and Iwona Flisiak
J. Clin. Med. 2024, 13(1), 109; https://doi.org/10.3390/jcm13010109 - 24 Dec 2023
Cited by 6 | Viewed by 2689
Abstract
Psoriasis is a chronic, complex, and immunologically mediated systemic disease that not only affects the skin, but also the joints and nails. It may coexist with various other disorders, such as depression, psoriatic arthritis, cardiovascular diseases, diabetes mellitus, and metabolic syndrome. In particular, [...] Read more.
Psoriasis is a chronic, complex, and immunologically mediated systemic disease that not only affects the skin, but also the joints and nails. It may coexist with various other disorders, such as depression, psoriatic arthritis, cardiovascular diseases, diabetes mellitus, and metabolic syndrome. In particular, the potential link between psoriasis and metabolic syndrome is an issue worthy of attention. The dysregulation of growth factors could potentially contribute to the disturbances of keratinocyte proliferation, inflammation, and itch severity. However, the pathophysiology of psoriasis and its comorbidities, such as metabolic syndrome, remains incompletely elucidated. Growth factors and their abnormal metabolism may be a potential link connecting these conditions. Overall, the objective of this review is to analyze the role of growth factor disturbances in both psoriasis and metabolic syndrome. Full article
(This article belongs to the Special Issue New Clinical Advances in Psoriasis and Psoriatic Arthritis)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-6
Back to TopTop